Sacituzumab Govitecan Shows Encouraging Results for Aggressive Endometrial Cancer

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, Senior Medical Editor, B. Pharm. Last updated on June 2, 2026.

via HealthDay

TUESDAY, June 2, 2026 -- A Trop-2-directed antibody-drug conjugate, sacituzumab govitecan (SG), demonstrates encouraging efficacy in a pretreated population with aggressive recurrent endometrial cancer (EC), according to a study published online May 14 in Clinical Cancer Research.

Alessandro D. Santin, M.D., from Yale University School of Medicine in New Haven, Connecticut, and colleagues conducted a phase 2, two-stage, open-label investigator-initiated trial involving patients with persistent/recurrent EC who had progressed following one or more prior chemotherapies. Fifty patients were screened and 21 enrolled during stage 1; 34 were screened and 29 enrolled during stage 2. Overall, 42 patients (84 percent) harbored serous carcinoma, carcinosarcoma, or grade 3 endometrioid tumors.

Patients had received a median of two prior therapies, and half had failed pembrolizumab/dostarlimab. The researchers found that the objective response rate was 28 percent at a median follow-up of 11 months, including complete response and partial response (4 and 24 percent, respectively). The median duration of response was 9.3 months; four patients were still responding. The clinical benefit ratio was 52 percent. Median progression-free survival was 5.5 months, and overall survival was 17.5 months. Eighty-eight percent of participants had grade 3 to 4 toxicity, with no attributable deaths. Mean H-scores, which assessed Trop-2 expression, did not predict response.

"The results of our Investigator Initiated Trial complement and extend the TROPiCS-03 Trial results by demonstrating significant clinical activity of SG not only against the most common histological types of uterine cancer (endometrioid tumors) but also in patients harboring biologically aggressive endometrial tumors such as uterine serous carcinoma and carcinosarcoma," Santin said in a statement.

One author disclosed ties to biopharmaceutical companies, including Gilead; the study drug was supplied by Gilead Sciences, Inc.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-06-03 03:42

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords